Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study

This study is testing a device that delivers gentle light energy to the brain (transcranial photobiomodulation, or tPBM) to see whether it can improve memory and thinking in people with mild cognitive impairment or early Alzheimer's disease. Participants attend weekly in-person treatment sessions at Cedars-Sinai Medical Center. **You may be eligible if...** - You are between 55 and 89 years old - You have been diagnosed with mild cognitive impairment or mild dementia likely due to Alzheimer's disease - Your memory and thinking scores fall within a specific range on standard tests (MoCA 16–25; CDR Global 0–1) - If you take Alzheimer's medications (such as donepezil or memantine), you have been on a stable dose for at least 4 weeks - You are able to attend weekly in-person visits at Cedars-Sinai **You may NOT be eligible if...** - You have another significant brain condition (such as epilepsy, Parkinson's disease, or large brain lesions) - You have a history of seizures - You have significant brain scan findings such as extensive white matter changes or many brain bleeds - You are currently pregnant or breastfeeding - You have participated in another clinical trial within the past 30 days - You have severe dementia Talk to your doctor to see if this trial is right for you.